GI大会上公表的一项IIT数据显示，索凡替尼联合AS疗法和卡瑞利珠单抗治疗1L PDAC 的ORRBocom Intl released a research report stating that it maintains a 'buy' rating for Hutchmed (China) (00013) with a target price of HKD 40.
According to the report, the company's catalysts in the second half of 2024 include global sales of fruquintinib and domestic approval progress for 2L gastric cancer based on the FRUTIGA study, global submission of savolitinib based on SAVANNAH study, and domestic approval of surufatinib.
The bank pointed out that the combination of surufatinib and PD-1 in the first-line treatment of pancreatic cancer is encouraging, and an IIT data presented at ASCO GI conference showed that the ORR of surufatinib combined with AS therapy and carrelizumab in the first-line treatment of PDAC is 50%, and the mPFS/mOS are 9 and 13.3 months, which is significantly better than existing therapies.
An IIT data presented at the GI conference showed that the ORR for first-line PDAC treatment with the combination of Sofosbuvir and AS therapy and Carilizumab was 50%, with mPFS/mOS of 9 and 13.3 months, respectively, which is significantly better than existing therapies.
At 50% ORR, the mPFS/mOS were 9 and 13.3 months, respectively, which is significantly better than existing therapies.